abstract |
A therapeutic composition whereby an individual suspected of having an alpha-galactosidase A deficiency, such as Fabry disease, comprising either (1) human cells that have been genetically modified to overexpress and secrete human alpha-gal A, or (2) purified human alpha-gal A obtained from cultured, genetically modified human cells. |